Establishment Labs (NASDAQ:ESTA – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Institutional and Insider Ownership
72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations and price targets for Establishment Labs and Nyxoah, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Establishment Labs | 1 | 0 | 8 | 0 | 2.78 |
| Nyxoah | 1 | 1 | 2 | 0 | 2.25 |
Risk and Volatility
Establishment Labs has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Valuation and Earnings
This table compares Establishment Labs and Nyxoah”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Establishment Labs | $211.08 million | 10.49 | -$51.06 million | ($1.31) | -56.71 |
| Nyxoah | $11.33 million | 5.54 | -$101.92 million | ($2.52) | -0.64 |
Establishment Labs has higher revenue and earnings than Nyxoah. Establishment Labs is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Establishment Labs and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Establishment Labs | -15.82% | -196.69% | -10.73% |
| Nyxoah | -443.16% | -178.90% | -81.83% |
Summary
Establishment Labs beats Nyxoah on 10 of the 14 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
